Search Videos by Topic or Participant
Browse by Series:

Frontline Treatment of Idiopathic Thrombocytopenic Purpura

Panelists: Howard A. Liebman, MD, USC; Keith McCrae, MD, Cleveland Clinic; Ivy Altomare, MD, Duke 
Published: Friday, Apr 24, 2015
For High-Definition, Click

Clinicians may initiate treatment of idiopathic thrombocytopenic purpura (ITP) to make a diagnosis, mitigate a risk of bleeding, or treat active bleeding. The decision to begin treatment for ITP should be individualized for each patient, states Ivy Altomare, MD. According to the recent ASH Guidelines and International Consensus Report, steroids are the standard first-line treatment for ITP. Although there are currently no clinical trial data recommending an exact course of steroids, Altomare notes that many practitioners use 1 mg per kg of prednisone.

Many clinicians will treat ITP until the platelet count normalizes, then treat for another week at that same dose followed by a gradual tapering. Howard A. Liebman, MD, mentions that patients who are asymptomatic with few manifestations (fatigue, bruises, nose bleeds) may not receive any treatment, even if their platelet counts are below 30,000. Liebman explains that these individuals should be closely followed and educated regarding the manifestations associated with bleeding, as well as circumstances that may aggravate their immune thrombocytopenia, such as concomitant infection or other medications they are taking.
Slider Left
Slider Right
For High-Definition, Click

Clinicians may initiate treatment of idiopathic thrombocytopenic purpura (ITP) to make a diagnosis, mitigate a risk of bleeding, or treat active bleeding. The decision to begin treatment for ITP should be individualized for each patient, states Ivy Altomare, MD. According to the recent ASH Guidelines and International Consensus Report, steroids are the standard first-line treatment for ITP. Although there are currently no clinical trial data recommending an exact course of steroids, Altomare notes that many practitioners use 1 mg per kg of prednisone.

Many clinicians will treat ITP until the platelet count normalizes, then treat for another week at that same dose followed by a gradual tapering. Howard A. Liebman, MD, mentions that patients who are asymptomatic with few manifestations (fatigue, bruises, nose bleeds) may not receive any treatment, even if their platelet counts are below 30,000. Liebman explains that these individuals should be closely followed and educated regarding the manifestations associated with bleeding, as well as circumstances that may aggravate their immune thrombocytopenia, such as concomitant infection or other medications they are taking.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x